LeMaitre Vascular (LMAT) Pullback Puts Its Valuation Narrative Back In Focus
Riverwater Partners recently called out LeMaitre Vascular (LMAT) after the stock weakened in the second quarter, arguing that sentiment rather than business fundamentals drove the move in this peripheral vascular device specialist.
Over the past year, LeMaitre Vascular has seen short term momentum fade, with a 1 month share price return down 21.13% and a 90 day share price return down 12.65%, even though the 3 year total shareholder return of 48.30% remains positive.
Scan how LeMaitre Vascular compares with a curated 75 resilient stocks with low risk scores list that has shown resilience when sentiment turns against quality healthcare stocks.
After a pullback that has taken LeMaitre Vascular shares down over the past quarter and year, some investors may see a reset, while others prefer to wait. The next step is to test that urge against valuation.
Most Popular Narrative: 26% Undervalued
The most followed narrative for LeMaitre Vascular pegs fair value at $110 against a last close of $81.72, so it frames the recent pullback as a discount worth examining more closely.
Strong pipeline of innovative biologics and next-generation products, combined with ongoing regulatory wins, enhances pricing power and product mix; this supports premium pricing and improved gross margins, with successful launches expected to materially contribute to long-term earnings growth.
Read the complete narrative. Read the complete narrative.
It may be useful to understand what sits behind that $110 fair value for LeMaitre Vascular. The narrative leans heavily on compounding revenue, steady margins and a richer earnings multiple. Readers may want to see which growth and profitability assumptions carry the most weight in that calculation.
Result: Fair Value of $110 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, LeMaitre Vascular still faces key risks, including dependence on price increases and a focused product portfolio that could be pressured by competitors and regulatory hurdles.
Find out about the key risks to this LeMaitre Vascular narrative.
Another View on LeMaitre Vascular’s Valuation
The most popular narrative frames LeMaitre Vascular as 26% undervalued at $110 fair value versus the current $81.72 share price. Our ratio based work tells a different story. The stock trades on a P/E of 28.5x, while the fair ratio is 23.1x.
That P/E is also slightly above the US Medical Equipment industry at 27x, yet sits below the peer group average of 32x. In practice, this mix of premium and discount means valuation risk cuts both ways. The key question is whether the market moves closer to the fair ratio or toward higher priced peers.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed sentiment around LeMaitre Vascular, it makes sense to move quickly and test the numbers yourself rather than rely on headlines. To see what is driving optimism and how those positives stack up against the risks, review the 2 key rewards
Looking for more investment ideas beyond LeMaitre Vascular?
If you want a clearer view of where to put fresh capital to work, let Simply Wall Street’s Screener help you uncover focused ideas before others catch on.
- Target potential mispricing by scanning a focused basket of quality companies using the 54 high quality undervalued stocks.
- Strengthen your defensive side by zeroing in on companies with robust finances through the list of solid balance sheet and fundamentals (52 results).
- Put income at the center of your watchlist by using the 11 dividend fortresses to spot stocks offering stronger yield profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com